Suppr超能文献

吉兰-巴雷综合征后的癌症诊断与预后:一项基于人群的队列研究。

Cancer Diagnosis and Prognosis After Guillain-Barré Syndrome: A Population-Based Cohort Study.

作者信息

Girma Blean, Farkas Dóra Körmendiné, Laugesen Kristina, Skajaa Nils, Henderson Victor W, Boffetta Paolo, Sørensen Henrik Toft

机构信息

Department of Environmental Medicine and Public Health, Icahn School of Medicine, New York, NY, USA.

Department of Clinical Epidemiology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.

出版信息

Clin Epidemiol. 2022 Jul 19;14:871-878. doi: 10.2147/CLEP.S369908. eCollection 2022.

Abstract

INTRODUCTION

It is unclear whether Guillain-Barré syndrome (GBS) can be a marker of a paraneoplastic syndrome. We examined whether GBS is associated with cancer and whether the prognosis of GBS patients with cancer differs from that of other cancer patients.

MATERIALS AND METHODS

We conducted a population-based cohort study of patients diagnosed with GBS between 1978 and 2017 using Danish registry-data. Main outcome measures were cancer incidence and mortality after cancer diagnosis. We calculated absolute risks of a cancer diagnosis, treating death as competing risk, and standardized incidence ratios (SIRs) as measures of relative risk. We matched each GBS cancer patient with up to 10 cancer patients without a GBS diagnosis and examined the six-month survival after cancer diagnosis using Cox regression analysis.

RESULTS

We identified 7897 patients (58% male, median age 57 years) with GBS. During a median follow-up of 9.5 years, the one-year risk of cancer was 2.7% (95% confidence interval (CI), 2.4-3.1). The SIR was increased throughout follow-up, but most noticeably during the first year after diagnosis (SIR: 3.35, 2.92-3.83). SIRs were particularly elevated for hematologic cancers (SIR: 8.67, 6.49-11.34), smoking-related cancers (SIR: 3.57, 2.81-4.47), and cancers of neurological origin (SIR: 8.60, 5.01-13.77). Lung cancer was the main contributor to the overall excess risk, which persisted after 36 months of follow-up (SIR: 1.17, 1.09-1.25). The mortality rate ratio comparing patients diagnosed with any cancer within one year of their GBS diagnosis and matched GBS-free cancer cohort members was 1.56 (95% CI, 1.27-1.90).

CONCLUSION

GBS patients had a three-fold increased risk of cancer diagnosis in the first year of follow-up. The absolute cancer risk was almost 3.0%. A GBS diagnosis was an adverse prognostic marker for survival following cancer diagnosis. Clinicians should consider occult cancer in patients hospitalized with GBS.

摘要

引言

吉兰 - 巴雷综合征(GBS)是否可能是副肿瘤综合征的一个标志物尚不清楚。我们研究了GBS是否与癌症相关,以及患有癌症的GBS患者的预后是否与其他癌症患者不同。

材料与方法

我们利用丹麦登记数据对1978年至2017年间诊断为GBS的患者进行了一项基于人群的队列研究。主要结局指标是癌症发病率和癌症诊断后的死亡率。我们将癌症诊断的绝对风险计算在内,将死亡视为竞争风险,并计算标准化发病率比(SIRs)作为相对风险的衡量指标。我们将每例GBS癌症患者与多达10例未诊断为GBS的癌症患者进行匹配,并使用Cox回归分析检查癌症诊断后的六个月生存率。

结果

我们确定了7897例GBS患者(58%为男性,中位年龄57岁)。在中位随访9.5年期间,癌症的一年风险为2.7%(95%置信区间(CI),2.4 - 3.1)。在整个随访期间SIR均升高,但在诊断后的第一年最为明显(SIR:3.35,2.92 - 3.83)。血液系统癌症(SIR:8.67,6.49 - 11.34)、与吸烟相关的癌症(SIR:3.57,2.81 - 4.47)以及神经源性癌症(SIR:8.60,5.01 - 13.77)的SIRs尤其升高。肺癌是总体额外风险的主要贡献者,在随访36个月后该风险仍然存在(SIR:1.17,1.09 - 1.25)。将在GBS诊断后一年内诊断为任何癌症的患者与匹配的无GBS癌症队列成员进行比较,死亡率比为1.56(95%CI,1.27 - 1.90)。

结论

GBS患者在随访的第一年癌症诊断风险增加了三倍。绝对癌症风险接近3.0%。GBS诊断是癌症诊断后生存的不良预后标志物。临床医生应考虑GBS住院患者存在隐匿性癌症的可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2037/9309322/e436d5280b2b/CLEP-14-871-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验